212 related articles for article (PubMed ID: 22725255)
1. Sorafenib in non-small cell lung cancer.
Zhang J; Gold KA; Kim E
Expert Opin Investig Drugs; 2012 Sep; 21(9):1417-26. PubMed ID: 22725255
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy in advanced non-small-cell lung cancer.
Gettinger S
Semin Respir Crit Care Med; 2008 Jun; 29(3):291-301. PubMed ID: 18506667
[TBL] [Abstract][Full Text] [Related]
3. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Cabebe E; Wakelee H
Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.
Kelly RJ; Rajan A; Force J; Lopez-Chavez A; Keen C; Cao L; Yu Y; Choyke P; Turkbey B; Raffeld M; Xi L; Steinberg SM; Wright JJ; Kummar S; Gutierrez M; Giaccone G
Clin Cancer Res; 2011 Mar; 17(5):1190-9. PubMed ID: 21224376
[TBL] [Abstract][Full Text] [Related]
5. [Tumor vasculature as a therapeutic target in non-small cell lung cancer].
Döme B; Magyar M
Magy Onkol; 2008 Sep; 52(3):247-59. PubMed ID: 18845495
[TBL] [Abstract][Full Text] [Related]
6. Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
Horn L; Sandler AB
Clin Lung Cancer; 2009 Mar; 10 Suppl 1(Suppl 1):S7-16. PubMed ID: 19362948
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib for lung cancer: is the "Battle" still open?
Bria E; Pilotto S; Tortora G
Expert Opin Investig Drugs; 2012 Oct; 21(10):1445-8. PubMed ID: 22799503
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib in lung cancer: clinical developments and future directions.
Blumenschein G
J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S124-7. PubMed ID: 18520294
[TBL] [Abstract][Full Text] [Related]
10. [Lung cancer].
Fischer B; Buhl R
Med Klin (Munich); 2008 May; 103(5):311-20. PubMed ID: 18484217
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib.
Hasskarl J
Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.
Lee CB; Socinski MA
Rev Recent Clin Trials; 2007 May; 2(2):117-20. PubMed ID: 18473996
[TBL] [Abstract][Full Text] [Related]
13. Combining anti-Epidermal Growth Factor Receptor (EGFR) and anti-angiogenic strategies in advanced NSCLC: we should have known better….
Di Maio M; Morabito A; Piccirillo MC; Daniele G; Giordano P; Costanzo R; Sandomenico C; Montanino A; Rocco G; Perrone F
Curr Pharm Des; 2014; 20(24):3901-13. PubMed ID: 24191956
[TBL] [Abstract][Full Text] [Related]
14. NSCLC drug targets acquire new visibility.
Friedrich MJ
J Natl Cancer Inst; 2011 Mar; 103(5):366-7. PubMed ID: 21357596
[No Abstract] [Full Text] [Related]
15. Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Okamoto I; Miyazaki M; Morinaga R; Kaneda H; Ueda S; Hasegawa Y; Satoh T; Kawada A; Fukuoka M; Fukino K; Tanigawa T; Nakagawa K
Invest New Drugs; 2010 Dec; 28(6):844-53. PubMed ID: 19760364
[TBL] [Abstract][Full Text] [Related]
16. A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501.
Wakelee HA; Lee JW; Hanna NH; Traynor AM; Carbone DP; Schiller JH
J Thorac Oncol; 2012 Oct; 7(10):1574-82. PubMed ID: 22982658
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of motesanib diphosphate in non-small-cell lung cancer.
Rijavec E; Genova C; Barletta G; Biello F; Dal Bello MG; Coco S; Truini A; Vanni I; Alama A; Boccardo F; Grossi F
Expert Opin Pharmacother; 2014 Aug; 15(12):1771-80. PubMed ID: 25032887
[TBL] [Abstract][Full Text] [Related]
18. The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines.
Jiang Y; Li C; Ma Y; Chen J; Li Y; Chen L
Clin Lab; 2012; 58(5-6):551-61. PubMed ID: 22783588
[TBL] [Abstract][Full Text] [Related]
19. Drug insight: VEGF as a therapeutic target for breast cancer.
Schneider BP; Sledge GW
Nat Clin Pract Oncol; 2007 Mar; 4(3):181-9. PubMed ID: 17327858
[TBL] [Abstract][Full Text] [Related]
20. The role of antiangiogenesis therapy: bevacizumab and beyond.
Cortés-Funes H
Clin Transl Oncol; 2009 Jun; 11(6):349-55. PubMed ID: 19531449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
